>

Beatrice Mauro - Roche Holdings Non-Executive Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>RHH</div>
RHHBF -- USA Stock  

USD 349.00  4.15  1.18%

  Director
Prof. Dr. Beatrice Weder di Mauro is NonExecutive Director at Roche Holding AG since 2006. In addition she acts as Member of the Audit Committee of the Company. She studied at Universitaet Basel Department of Economics where she gained a Doctorate degree in 1993. From 1993 until 1994 Prod. Dr. Weder di Mauro was PostDoctoral Research Fellow at the University of Basel. From 1994 until 1996 she was Economist at the International Monetary Fund Washington D.C. From 1996 until 1997 Prof. Dr. Weder di Mauro was Economist at the World Bank Washington D.C. From 1997 until 1998 she was Research Fellow at the United Nations University Tokyo. From 1998 until 2001 she was Assistant Professor of Economics at the Universitae Basel. Since 2001 she was Professor of Economics at the University of Mainz and since 2004 Prof. Dr. Weder di Mauro was Member of the German Council of Economic Experts. She was Member of the Board of Macroeconomic Advisors of the Swiss Federation from 2002 until 2004. From 2001 until 2004 she was Member of the Scientific Advisory Board of the Institute for Economic Research in Hamburg. From 2002 until 2004 she was CoEditor of Applied Economics Quarterly in Berlin. Prof. Dr. Weder di Mauro is Member of the Supervisory Board of ERGO Insurance Group since 2005. Since 2003 she was Research Fellow at the Center For Economic Policy Research and since 2005 she was Member of the Steering Committee of the Group The Macroeconomics of Global Interdependence. She is Member of Committee on International Economics of the Verein fuer Socialpolitik since 2005. Prof. Dr. Weder di Mauro is Research Fellow at the Center for Financial Studies in Frankfurt since 1999 among others.
Age: 49  Director Since 2006      
41 61 688 11 11  http://www.roche.com

Management Efficiency

The company has return on total asset (ROA) of 15.83 % which means that it generated profit of $15.83 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 42.6 % meaning that it generated $42.6 on every $100 dollars invested by stockholders.
The company has accumulated 20.91 B in total debt with debt to equity ratio (D/E) of 43.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Roche Holdings Ag has Current Ratio of 1.27 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Baroness VaderaAstrazeneca PLC
2011
Stacey CartwrightGlaxoSmithKline PLC
2011
Karen VousdenBristol Myers Squibb Company
2018
Diane SouzaSanofi
2016
Paul RothmanMerck Company
2015
David HooverEli Lilly And Company
2009
Philip BroadleyAstrazeneca PLC
2017
SuetFern LeeSanofi
2011
Anne MulcahyJohnson Johnson
2012
Leslie BrunMerck Company
2016
Marcus WallenbergAstrazeneca PLC
1999
Ronald BlaylockPfizer
2017
Daniel PodolskyGlaxoSmithKline PLC
2006
Urs RohnerGlaxoSmithKline PLC
2015
Juan LucianoEli Lilly And Company
2016
John NoseworthyMerck Company
2017
Ann CairnsAstrazeneca PLC
2014
Karen HornEli Lilly And Company
2012
Theodore SamuelsBristol Myers Squibb Company
2017
James SmithPfizer
2014
Craig ThompsonMerck Company
2008

Company Summary

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. The company was founded in 1896 and is headquartered in Basel, Switzerland. Roche Holdings operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 97735 people.Roche Holdings Ag Beare [RHHBF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Roche Holdings Ag Leadership Team

Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of ChugaiView
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early DevelopmentView
Silvia Ayyoubi, Head of Group HRView
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche PartneringView
Beatrice Mauro, Non-Executive DirectorView
Cristina Wilbur, Member of the Executive Committee, Head Group Human ResourcesView
William Anderson, Member of the Corporate Executive Committee, CEO Roche PharmaceuticalsView
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche DiagnosticsView
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma PartneringView
Gottlieb Keller, General Counsel and Corporate SecretaryView
Urs Jaisli, Chief Compliance OfficerView
Daniel ODay, COO of Pharmaceuticals divisionView
DeAnne Julius, Non-Executive DirectorView
Karl Mahler, Head of Investor RelationsView
Andre Hoffmann, Non-Executive Vice Chairman of the BoardView
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early DevelopmentView
Claudia Dyckerhoff, Non-Executive DirectorView
Fritz Gerber, Honorary Chairman of the BoardView
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group CommunicationsView
Julie Brown, Non-Executive DirectorView
Richard Lifton, Non-Executive DirectorView
Paul Bulcke, Non-Executive DirectorView
Christoph Franz, Non-Executive DirectorView
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO OfficeView
Pius Baschera, Non-Executive DirectorView
Peter Voser, Non-Executive DirectorView
Bernard Poussot, Non-Executive DirectorView
John Bell, Non-Executive DirectorView
Andreas Oeri, Non-Executive DirectorView
Alan Hippe, CFO and IT OfficerView
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED)View
F Hoffmann, IR Contact OfficerView
Severin Schwan, CEO and DirectorView
Anita Hauser, Non-Executive DirectorView
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche DiagnosticsView

Stock Performance Indicators

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Currently Active Assets on Macroaxis

DSTL   
Purchased over 400 shares of
few hours ago
Traded for 31.54
PG   
Purchased over 100 shares of
few hours ago
Traded for 125.44
KO   
Purchased over 100 shares of
few hours ago
Traded for 59.77
FNCIX   
Purchased over 100 shares of
few hours ago
Traded for 11.91
CAFCX   
Purchased over 100 shares of
few hours ago
Traded for 30.64
Additionally take a look at Your Equity Center. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.